HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Faces More Tech Hurdles After Clearing AERs Backlog, And Congress Is Watching

This article was originally published in The Tan Sheet

Executive Summary

Congressional scrutiny of FDA’s overall document management challenges is unlikely to let up despite the agency’s clearing of its adverse event reports backlog. Rep. Michael Burgess hit FDA’s document management practices hard during the first formal hearing on the 21sy Century Cures initiative.

You may also be interested in...



Congress Dives Into Biomedical Innovation: Will It Drown In A Deep Sea Of Competing Needs?

House Energy and Commerce committee says it’s committed to a bill to accelerate U.S. biomedical innovation before the next FDA user fee cycle, but the wide scope of needs and stakeholders may make crafting legislation challenging – never mind getting it passed.

CDER Wants To Become “Lean”; Plans Process Analysis

Strategic plan says CDER will streamline its processes and may find activities that could be “cut altogether.”

FDA Seeks New Chief Information Officer In Privacy And Security Overhaul

The CIO will help develop policy to protect sensitive information while balancing individual privacy and security. FDA restructured the organization with a chief health informatics officer – focused on research, development, scientific computing and big data – and the CIO for software development and deployment, infrastructure and customer service.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS139415

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel